IYH:NYE-iShares U.S. Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 61.74

Change

-0.33 (-0.53)%

Market Cap

N/A

Volume

0.47M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-27 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.60 (-0.41%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

-0.45 (-0.65%)

USD 2.77B
FXH First Trust Health Care AlphaD..

-1.52 (-1.41%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-2.89 (-3.18%)

USD 0.20B
IDNA iShares Genomics Immunology an..

-0.23 (-1.02%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.20 (-0.65%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.03 (+0.03%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.78 (-2.63%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.44 (-0.71%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.35 (-1.70%)

USD 6.67M

ETFs Containing IYH

RXD ProShares UltraShort Heal.. 10.32 % 0.77 %

+0.09 (+0.90%)

N/A
RXD ProShares UltraShort Heal.. 10.32 % 0.95 %

+0.09 (+0.90%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.96% 71% C- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.96% 71% C- 81% B-
Trailing 12 Months  
Capital Gain 1.78% 62% D 43% F
Dividend Return 1.20% 81% B- 21% F
Total Return 2.98% 67% D+ 33% F
Trailing 5 Years  
Capital Gain 57.08% 95% A 69% C-
Dividend Return 8.05% 74% C 20% F
Total Return 65.13% 95% A 65% D
Average Annual (5 Year Horizon)  
Capital Gain 5.90% 71% C- 53% F
Dividend Return 6.91% 76% C+ 49% F
Total Return 1.01% 79% B- 24% F
Risk Return Profile  
Volatility (Standard Deviation) 18.43% 52% F 59% D-
Risk Adjusted Return 37.50% 71% C- 51% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike